|Mr. Dominick C. Colangelo Esq.||CEO, Pres & Director||1.16M||1.88M||1964|
|Mr. Gerard J. Michel||CFO & VP of Corp. Devel.||616.48k||1.61M||1963|
|Mr. Michael Halpin||Chief Operating Officer||568.1k||617.58k||1961|
|Mr. Sean C. Flynn||VP, Gen. Counsel & Corp. Sec.||N/A||N/A||N/A|
|Ms. Heidi Hassen||VP of HR||N/A||N/A||N/A|
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. It markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to dilated cardiomyopathy. In addition, its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for debridement of severe thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Vericel Corporation’s ISS Governance QualityScore as of December 8, 2019 is 6. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 5; Compensation: 6.